Akili, Inc. (AKLI)
| Market Cap | 38.14M |
| Revenue (ttm) | 1.04M |
| Net Income (ttm) | -65.16M |
| Shares Out | 78.31M |
| EPS (ttm) | -1.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,003 |
| Open | 0.460 |
| Previous Close | 0.477 |
| Day's Range | 0.450 - 0.525 |
| 52-Week Range | 0.280 - 2.200 |
| Beta | 1.85 |
| Analysts | Buy |
| Price Target | 3.50 (+618.54%) |
| Earnings Date | Nov 9, 2023 |
About AKLI
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, ... [Read more]
Financial Performance
In 2022, Akili's revenue was $323,000, a decrease of -39.96% compared to the previous year's $538,000. Losses were -$19.04 million, -84.97% less than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for AKLI stock is "Buy." The 12-month stock price forecast is $3.5, which is an increase of 618.54% from the latest price.
News
Akili Reports Third Quarter 2023 Financial Results and Provides Business Update
BOSTON--(BUSINESS WIRE)--Akili Reports Third Quarter 2023 Financial Results and Provides Business Update.
Akili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ET
BOSTON--(BUSINESS WIRE)--Akili to Host Third Quarter Financial Results Conference Call on Thursday, November 9 at 4:30 p.m.
Employees with ADHD Aren't Reaching Their Full Potential at Work, Akili Study Finds
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), the leading digital medicine company behind EndeavorOTC™, today released results from a new study examining the ways in which ADHD impacts the U.S....
Akili Announces Leadership Transition
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that Eddie Martucci transitioned to the role of Board chair, and Matt Franklin has been appoint...
Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD
BOSTON--(BUSINESS WIRE)--Akili Releases EndeavorOTC on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD.
Akili Announces Business Transformation, Focusing on Non-prescription Model
BOSTON--(BUSINESS WIRE)--Akili plans transition to non-Rx business, increasing patient access to clinically-proven non-drug treatments and reducing reliance on intermediaries.
Akili Reports Second Quarter 2023 Financial Results and Provides Business Update
BOSTON--(BUSINESS WIRE)--Akili Reports Second Quarter 2023 Financial Results and Provides Business Update.
Akili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ET
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the second quarter of...
Akili Releases EndeavorOTCTM Video Game Treatment to Improve Attention in Adults with ADHD
BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Adults with ADHD can now improve their attention & focus with a new clinically-proven mobile video game treatment. Available now in the iOS App Store.
Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress
BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Akili To Presents Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at Upcoming Scientific Meetings.
Akili Reports First Quarter 2023 Financial Results and Provides Business Update
BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2023, and provided an upda...
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili's EndeavorRx® Video Game-Based Therapeutic
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Announces Topline Results of the STARS-ADHD-Adult Clinical Trial.
Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili's EndeavorRx® Video Game-Based Therapeutic
BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Adults with ADHD improve their attention and quality of life using EndeavorRx video game treatment in clinical trial.
Akili to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 11 at 4:30 p.m. ET
BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the f...
Akili Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2022, and provided an upd...
Akili to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, March 7 at 4:30 p.m. ET
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the fourth quarter ...
Akili to Participate in the Cowen 43rd Annual Health Care Conference
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Cowen 43rd Annual Health Care Conference in Boston next month.
Akili to Champion Digital Therapeutics in Conjunction with J.P. Morgan Healthcare Conference
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Biotech Showcase and Solebury 1x1 Management Access Conference, both happening alongs...
Pivotal Trial of EndeavorRxⓇ in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced topline results of the STARS-ADHD-Adolescents label expansion study evaluating the efficacy a...
Akili Announces ADHD Expert Dr. Scott Kollins to Join as Chief Medical Officer
BOSTON--(BUSINESS WIRE)--Akili, Inc., a leading commercial digital medicine company, today announced the appointment of Scott Kollins, Ph.D., as chief medical officer, effective December 1, 2022. Dr...
Akili Reports Third Quarter 2022 Financial Results and Company Update
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended September 30, 2022, and provided an update on busi...
Financial Industry Veteran Mary Hentges Joins Akili's Board of Directors
BOSTON--(BUSINESS WIRE)--Akili, Inc. (NASDAQ: AKLI), a leading digital medicine company, today announced the appointment of Mary Hentges to the company's board of directors, effective October 25, 2022...
Akili to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 10 at 4:30 p.m. ET
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its third quarter financial results on Thursday, November 10,...
Akili Launches EndeavorRx® Expedition - A Direct-to-Patient Product Registry
BOSTON--(BUSINESS WIRE)---- $AKLI--Akili Interactive (“Akili”), a leading digital medicine company, today announced the EndeavorRx® Expedition product registry, which aims to obtain feedback from pati...
Akili to Participate in LifeSci Partners HealthTech Symposium
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that management will present at a fireside chat and participate in a panel discussion on prescr...